Video

Experts Share Common Misconceptions in Their Fields

Author(s):

OncLive Staff

In Partnership With:

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Milind Javle, MD; Rachna Shroff, MD, MS, FASCO
Related Content
FDA
May 31st 2024

FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Shadmehr Demehri, MD, PhD
May 30th 2024

Pitavastatin Offers Therapeutic Potential in Cancers Arising From Chronic Inflammation

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Rob Iannone, MD, MSCE
May 29th 2024

FDA Grants Priority Review to Zanidatamab for HER2+ Metastatic Biliary Tract Cancer

Pancreatic Cancer
May 29th 2024

CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer